Navigation Links
Sinovac Holds 2011 Annual Shareholders Meeting
Date:7/14/2011

ckpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

Safe Harbor StatementThis announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.CONTACT:Helen Yang/Chris LeeSinovac Biotech Ltd.Tel: +86-10-8279-9871/9659Fax: +86-10-6296-6910Email: ir@sinovac.comInvestors:Stephanie CarringtonThe Ruth GroupTel: +1-646-536-7017Email: scarrington@theruthgroup.comMedia:Victoria AguiarThe Ruth GroupTel: +1-646-536-7013Email: vaguiar
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Sinovac Appoints Kenneth Lee to Board of Directors
2. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
3. Sinovac Reports Unaudited First Quarter 2011 Financial Results
4. Sinovac Presents at Two Investor Conferences in May 2011
5. Sinovac Files Annual Report on Form 20-F
6. Sinovac Participates in UBS Greater China Healthcare Corporate Day
7. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
8. Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
9. Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range
10. Sinovacs Stock Exchange Listing Moves to NASDAQ Global Select Market
11. Sinovac Receives SFDA Approval to Commence Clinical Trials for Inactivated Enterovirus Type 71 Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)...   Polymer Technology Systems, Inc. (PTS) ... to integrate the CardioChek ® PA ... health systems across the country. The CardioChek PA ... through Hanson Medical Systems , offers immediate, ... cholesterol, triglycerides, and glucose. (Logo: ...
(Date:6/17/2013)... Quebec , June 17, 2013 Valeant Pharmaceuticals ... announced today that it has filed a preliminary prospectus supplement ... has today made a similar filing with securities regulatory authorities ... in connection with a public offering of its common ... "Offering"). The Company will also grant to the ...
(Date:6/17/2013)... , June 17, 2013  A little known drug industry ... scrutiny by the U.S. Supreme Court – and a ruling ... could not have come at a better time for New ... from the Rx industry tactic are all too apparent in ... 50+ New Yorkers, state residents are in a near Rx ...
Breaking Medicine Technology:Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 2Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 3
... VOLC ), a leading developer and manufacturer of ... and treatment of coronary and peripheral vascular disease, today announced ... quarter of fiscal 2011 on Monday, October 31. ... financial results and operating activities open to all interested parties ...
... VIEW, Calif., Oct. 17, 2011 ChemoCentryx, Inc., ... clinical trial for CCX168, an orally-administered small molecule ... vasculitis (AAV), a disease which can lead to ... C5a receptor (C5aR), a potent pro-inflammatory mediator that ...
Cached Medicine Technology:Volcano Corporation Schedules Third Quarter Conference Call, Webcast 2ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 2ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 3ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 4
(Date:6/18/2013)... By studying one of the most successful ... of successful strategies in his article What We Can ... Study. , The inspirational brand Gollan refers to is ... an impressive 62 million followers (and rising). , The ... Facebook Pages earlier this year. The Facebook data tracking publication ...
(Date:6/18/2013)... Lesbian, Gay, Bisexual and Transgender (LGBT) Pride ... sexual minority youth are still at greater ... according to the Suicide Prevention Resource Center. ... recently published recommendation to improve psychologists, treatment ... improve psychological functioning and reduce depression and ...
(Date:6/18/2013)... system using a person,s DNA was announced as ... London Startup Competition, Europe,s largest technology conference. ... on University of Bristol research by its founders, ... Professor of Bioinformatics in the University,s Department of ... to be one of 16 finalists in the ...
(Date:6/18/2013)... AZ (PRWEB) June 18, 2013 ... Stevie® Award in the Company of the Year category ... last night. , The American Business Awards are the ... the U.S.A. are eligible to submit nominations – public ... , Nicknamed the Stevies for the Greek word for ...
(Date:6/18/2013)... cough outbreaks are more likely to die prematurely even ... in Sweden has found. Women had a 20% higher ... 40%. Women also suffered more complications during and after ... as infant death within the first month of life. ... patients with exposure to whooping cough in childhood, particularly ...
Breaking Medicine News(10 mins):Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 2Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 3Health News:Sexual minority youth need specialized treatment from therapists 2Health News:CyraCom International, Inc. Honored as a Gold Stevie® Award Winner in 2013 American Business Awards 2Health News:CyraCom International, Inc. Honored as a Gold Stevie® Award Winner in 2013 American Business Awards 3
... MADISON, N.J., Nov. 8 Wyeth (NYSE: WYE ... Suisse First Boston,Healthcare Conference on Tuesday, November 13, 2007 ... Joseph M. Mahady, Senior Vice President,Wyeth and President, Wyeth ... live for investors at, http://www.wyeth.com and available for ...
... Mutual and Ohio Farm Bureau,Federation (OFBF) have announced ... to OFBF,s more than 230,000 members. Effective ... access to,Medical Mutual,s SuperMed provider network, the most ... providers in Ohio. Medical,Mutual and OFBF have worked ...
... for injury, study finds , THURSDAY, Nov. 8 (HealthDay ... medications may cut their risk for fracture, Canadian researchers ... there,s an increased risk of additional fractures, other health ... in osteoporosis patients are hip, spine, and wrist fractures. ...
... Focusing on his experience as a physician in ... Harris, MD, FACP, president-elect of the American College of ... Committee Subcommittee on Regulations, Healthcare and Trade. , ... financial struggles that Medicare payments to physicians played on ...
... Va. (Nov. 8, 2007) Virginia Commonwealth University researchers ... that play a major role in clotting disorders, which ... the lungs and those localized deep in the body ... occur when the effect of thrombin, a protein involved ...
... Nov. 8 Pathwork Diagnostics, a,genomics-based diagnostics company ... Origin Test is the focus of two studies ... Meeting of the Association,for Molecular Pathology (November 7-10, ... help determine a tumor,s origin so that,tissue-specific management ...
Cached Medicine News:Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 2Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 3Health News:Sticking With Meds Lowers Elderly Fracture Risk 2Health News:Looming Medicare cuts will disproportionately hurt physicians in small practices 2Health News:Researchers identify molecules with interesting anti-clotting properties 2Health News:Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics' Tissue of Origin Test 2Health News:Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics' Tissue of Origin Test 3
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
Clear Vinyl Urethral Catheters (100% Latex Free)...
100% Silicone Foley Catheter Kits 2-Way...
Medicine Products: